437 related articles for article (PubMed ID: 15055138)
1. CNS-aspergillosis: are there new treatment options?
Schwartz S; Thiel E
Mycoses; 2003; 46 Suppl 2():8-14. PubMed ID: 15055138
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
Clemons KV; Espiritu M; Parmar R; Stevens DA
Antimicrob Agents Chemother; 2005 Dec; 49(12):4867-75. PubMed ID: 16304147
[TBL] [Abstract][Full Text] [Related]
3. Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.
Schwartz S; Ruhnke M; Ribaud P; Reed E; Troke P; Thiel E
Mycoses; 2007 May; 50(3):196-200. PubMed ID: 17472616
[TBL] [Abstract][Full Text] [Related]
4. [Invasive aspergillosis: clinical manifestations and treatment].
Lumbreras C; Gavaldá J
Rev Iberoam Micol; 2003 Sep; 20(3):79-89. PubMed ID: 15456363
[TBL] [Abstract][Full Text] [Related]
5. The role of voriconazole in the treatment of central nervous system blastomycosis.
Ta M; Flowers SA; Rogers PD
Ann Pharmacother; 2009 Oct; 43(10):1696-700. PubMed ID: 19724015
[TBL] [Abstract][Full Text] [Related]
6. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
[TBL] [Abstract][Full Text] [Related]
7. Multi-azole resistance in Aspergillus fumigatus.
Howard SJ; Webster I; Moore CB; Gardiner RE; Park S; Perlin DS; Denning DW
Int J Antimicrob Agents; 2006 Nov; 28(5):450-3. PubMed ID: 17034993
[TBL] [Abstract][Full Text] [Related]
8. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
Sutton DA; Sanche SE; Revankar SG; Fothergill AW; Rinaldi MG
J Clin Microbiol; 1999 Jul; 37(7):2343-5. PubMed ID: 10364610
[TBL] [Abstract][Full Text] [Related]
9. Improved outcome in central nervous system aspergillosis, using voriconazole treatment.
Schwartz S; Ruhnke M; Ribaud P; Corey L; Driscoll T; Cornely OA; Schuler U; Lutsar I; Troke P; Thiel E
Blood; 2005 Oct; 106(8):2641-5. PubMed ID: 15998833
[TBL] [Abstract][Full Text] [Related]
10. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
[TBL] [Abstract][Full Text] [Related]
11. A case of Aspergillus mediastinitis after heart transplantation successfully treated with liposomal amphotericin B, caspofungin and voriconazole.
Forestier E; Remy V; Lesens O; Martinot M; Hansman Y; Eisenmann B; Christmann D
Eur J Clin Microbiol Infect Dis; 2005 May; 24(5):347-9. PubMed ID: 15889298
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman.
Elter T; Sieniawski M; Gossmann A; Wickenhauser C; Schröder U; Seifert H; Kuchta J; Burhenne J; Riedel KD; Fätkenheuer G; Cornely OA
Int J Antimicrob Agents; 2006 Sep; 28(3):262-5. PubMed ID: 16908120
[TBL] [Abstract][Full Text] [Related]
13. Combination antifungal therapy for invasive aspergillosis.
Cesaro S; Visintin G
Clin Infect Dis; 2005 Apr; 40(7):1073-5; author reply 1075-6. PubMed ID: 15825015
[No Abstract] [Full Text] [Related]
14. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole.
Ullmann AJ
Curr Med Res Opin; 2003; 19(4):263-71. PubMed ID: 12841918
[TBL] [Abstract][Full Text] [Related]
15. [Experience with voriconazole in invasive aspergillosis].
Thiel E; Schwartz S
Mycoses; 2003; 46 Suppl 2():3-7. PubMed ID: 15055137
[TBL] [Abstract][Full Text] [Related]
16. Use of newer antifungal therapies in clinical practice: what do the data tell us?
Perfect JR
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):15-23. PubMed ID: 15651178
[TBL] [Abstract][Full Text] [Related]
17. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS
Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408
[TBL] [Abstract][Full Text] [Related]
18. Triple antifungal therapy for the treatment of invasive aspergillosis in a neutropenic pediatric patient.
Sims-McCallum RP
Am J Health Syst Pharm; 2003 Nov; 60(22):2352-6. PubMed ID: 14652986
[No Abstract] [Full Text] [Related]
19. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
20. [New antifungal agents: voriconazole and caspofungin].
Dupont B
Arch Pediatr; 2003 Dec; 10 Suppl 5():592s-598s. PubMed ID: 15022787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
